Evaxion Biotech A/S
EVAXHealthcare|Biotechnology|DK
$3.00
+0.24 (+8.70%)
DCF Value
$33.35
Tangible Book / Share
$22.86
Cash / Share
$33.57
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04455503 Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Melanoma Stage IV, Melanoma Stage III | P1P2 | Terminated | 15 | Open-label | EVX-02A, EVX-02B, EVX-02A OR EVX-02B |
| NCT05309421 A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | Melanoma Stage IV, Unresectable Melanoma | P2 | Completed | 17 | Open-label | EVX-01, Pembrolizumab 25 MG/ML |